信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

盘前交易 06-01 06:43:32 EDT

4.51

-0.02

-0.44%

盘前4.38

-0.13-2.88%

05:41 EDT

最高4.58	最低4.48	成交量21.23万
今开4.52	昨收4.53	日振幅2.21%
总市值2.16亿	流通市值1.54亿	总股本4,788万
成交额96.08万	换手率0.62%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.51,"timestamp":1780084800000,"preClose":4.53,"halted":0,"volume":212315,"hourTrading":{"tag":"盘前","latestPrice":4.38,"preClose":4.51,"latestTime":"05:41 EDT","volume":68,"amount":302.700028,"timestamp":1780306875229,"change":-0.13,"changeRate":-0.028825,"amplitude":0.059867},"delay":0,"changeRate":-0.004415011037527695,"floatShares":34233044,"shares":47884104,"eps":0.209971,"marketStatus":"盘前交易","change":-0.02,"latestTime":"06-01 06:43:32 EDT","open":4.52,"high":4.5799,"low":4.48,"amount":960838.32658,"amplitude":0.022053,"askPrice":5.18,"askSize":100,"bidPrice":3.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.209971,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780320600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.51,"dividendRate":0.039911,"preHourTrading":{"tag":"盘前","latestPrice":4.38,"preClose":4.51,"latestTime":"05:41 EDT","volume":68,"amount":302.700028,"timestamp":1780306875229,"change":-0.13,"changeRate":-0.028825,"amplitude":0.059867},"postHourTrading":{"tag":"盘后","latestPrice":4.51,"preClose":4.51,"latestTime":"19:13 EDT","volume":9932,"amount":44793.57,"timestamp":1780096424337,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8170115731846785,"impliedVol":1.3209,"impliedVolPercentile":0.656},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2640935521","title":"港股异动 | 开拓药业-B(09939)涨超10% KX-826 III期数据亮相WCHR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640935521","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640935521?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:12","pubTimestamp":1780294340,"startTime":"0","endTime":"0","summary":"消息面上，6月1日，开拓药业宣布，自主研发、潜在同类首创的KX-826于2026年5月28日至31日在韩国首尔举行的第14届世界毛发研究大会上公布了两项重要临床研究数据。整体结果显示，KX-826在治疗脱发患者中展现出优异的有效性和安全性。该项临床观察试验由江蕾微教授等主导完成，为未来开展KX-826与米诺地尔联合疗法的III期临床试验提供了充分依据。公司表示目前正在积极推动KX-826的上市许可申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK1574","BK1515","BK4588","09939","BK4585","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981528","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)新辅助治疗BC的III期临床研究结果于2026 ASCO年会以LBA口头报告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981528","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981528?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:18","pubTimestamp":1780273113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团附属公司津曼特生物合作开发的安尼妥单抗联合注射用多西他赛新辅助治疗HER2+ BC的III期临床研究的显著性结果已于2026 ASCO年会以LBA口头报告形式呈列。KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评估安尼妥单抗联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在早期及局部晚期HER2+ BC新辅助治疗中的疗效与安全性，主要终点为由BIRC评估的 tpCR。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","III","BK1161","BK4190","09966","BK4134","BC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640813439","title":"石药集团(01093)：KN026联合HB1801新辅助治疗HER2阳性乳腺癌的III期临床研究结果于2026年ASCO年会以LBA口头报告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640813439","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640813439?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:13","pubTimestamp":1780272820,"startTime":"0","endTime":"0","summary":"Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1807302812.USD","LU0072913022.USD","BK4134","LU1226287529.USD","LU0314109678.HKD","IE0008368742.USD","LU0067412154.USD","LU0501845795.SGD","LU1951186391.HKD","LU1993786604.SGD","LU1813983027.USD","IE00B031HY20.USD","LU1226288253.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","LU1328277881.USD","LU1226287875.USD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU1008478684.HKD","SG9999004220.SGD","LU1152091754.HKD","IE0008369823.USD","IE00B543WZ88.USD","BK1191","01093","BK1515","LU1152091168.USD","BK1521","III","LU0326950275.SGD","LU1226288170.HKD","LU1960683339.HKD","LU0315179316.USD","HK0000165453.HKD","LU2039709279.SGD","LU0140636845.USD","LU0880133367.SGD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989899","title":"中国生物制药(01177)：贝莫苏拜单抗联合安罗替尼一线治疗非鳞状非小细胞肺癌于2026 ASCO公布III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989899","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640989899?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:58","pubTimestamp":1780268296,"startTime":"0","endTime":"0","summary":"这是继鳞状非小细胞肺癌之后，贝莫苏拜单抗联合安罗替尼在头对头III期临床研究中再次证实优效于替雷利珠单抗联合标准化疗方案，并成为全球首个在非鳞状非小细胞肺癌一线治疗中，相较于“免疫检查点抑制剂联合化疗”取得阳性结果的III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1191","BK1515","BK1589","BK1521","BK4134","IE00BZ08YS42.EUR","III","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640986039","title":"开拓药业-B(09939)：KX-826于WCHR 2026公布治疗雄激素脱发的III期临床试验及联合治疗研究数据，并获选杰出海报","url":"https://stock-news.laohu8.com/highlight/detail?id=2640986039","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640986039?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:41","pubTimestamp":1780267278,"startTime":"0","endTime":"0","summary":"整体结果显示，KX-826 在治疗脱发患者中展现出优异的有效性和安全性。与米诺地尔联合治疗中国成年男性脱发的临床观察试验研究数据。该项临床观察试验由江蕾微教授等主导完成，为未来开展KX-826与米诺地尔联合疗法的III期临床试验提供了充分依据。目前，公司正在积极推动KX-826的上市许可申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1574","III","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639725276","title":"BMS多发性骨髓瘤III期数据亮眼 C4 Therapeutics受提振大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2639725276","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639725276?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:49","pubTimestamp":1780084140,"startTime":"0","endTime":"0","summary":"百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这一积极结果不仅推高了施贵宝的股价，也显著提振了同领域生物科技公司C4 Therapeutics的市场表现。　　在施贵宝宣布这一消息后，C4 Therapeutics股价应声大涨，盘中一度触及52周新高，最终收涨逾19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-30/doc-inhzrera0552232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CCCC","III","BK4134","BK4139","BK4007","BK4539","BMS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639644648","title":"港股异动 | 中国生物制药(01177)涨超4% 与GSK合作的Bepirovirsen将于EASL 2026公布两项III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639644648","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639644648?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:33","pubTimestamp":1780036423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨3.95%，报5港元，成交额4.28亿港元。消息面上，5月29日，中国生物制药发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的Bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。Bepirovirsen目前正在接受中国、美国、欧洲、日本监管机构的审评审批。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","BK4585","01177","III","BK4134","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","BK4007","BK1589","BK1191","GSK","GSK.UK","BK4588","IE00BZ08YS42.EUR","BK1515","VXUS","GSKH","BK1521","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639648279","title":"港股异动 | 德琪医药-B(06996)涨超5% ATG-022 ADC治疗相关胃腺癌关键性III期CLINCH-3研究获临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639648279?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4134","BK1574","06996","ADC","BK4231","III","VXUS","BK4588","BK4080","BK4585","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639143996","title":"中国生物制药(01177)：BEPIROVIRSEN于EASL 2026公布两项III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639143996","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639143996?lang=zh_cn&edition=full","pubTime":"2026-05-29 06:23","pubTimestamp":1780007004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。HBsAg的下降还与89%的肝癌和62%的全因死亡风险降低有关。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。该疾病每年约造成110万人死亡，并导致约56%的全球肝癌病例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1589","IE00BZ08YR35.GBP","BK1521","III","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR","BK1515","01177","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632546","title":"德琪医药-B(06996)：ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部(GEJ)腺癌的关键性III期CLINCH-3研究获中国临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632546","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638632546?lang=zh_cn&edition=full","pubTime":"2026-05-28 07:27","pubTimestamp":1779924430,"startTime":"0","endTime":"0","summary":"作为一项关键注册研究，CLINCH-3旨在支持ATG-022作为单药疗法治疗CLDN18.2+晚期胃癌或胃食管结合部腺癌的未来上市许可申请。本集团无法保证ATG-022最终将成功开发及上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","III","06996","BK4134","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638681039","title":"核心III期数据进入倒计时，Vistagen将出席Jefferies全球医疗保健年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638681039","media":"环球市场播报","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638681039?lang=zh_cn&edition=full","pubTime":"2026-05-27 23:28","pubTimestamp":1779895680,"startTime":"0","endTime":"0","summary":"专注于开发新型鼻内给药神经科学药物的Vistagen宣布，公司将出席于2026年6月2日至4日在纽约举行的Jefferies全球医疗保健年会。会议期间，公司管理层将与机构投资者进行一对一交流，介绍其创新的pherine候选药物管线的最新进展。　　Vistagen的先导候选药物fasedienol正处于美国注册导向的III期临床开发阶段，用于社交焦虑症的急性治疗。Vistagen认为，若其中任何一项III期试验成功，连同PALISADE-2的积极结果，可能构成提交新药上市申请所需的有效性实质证据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfve8244142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","LABU","BK4588","III","BK4585","BK4134","XBI","BK4581","VHT","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638832606","title":"上海医药：截至2026年第一季度B001项目用于治疗视神经脊髓炎（NMOSD）的III期临床试验主研究（RCP）已完成揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2638832606","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638832606?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:32","pubTimestamp":1779885120,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯，上海医药在接受调研者提问时表示，截至2026年第一季度，B001项目用于治疗视神经脊髓炎(NMOSD)的III期临床试验主研究(RCP)已完成揭盲。研究结果显示，B001较安慰剂可显著降低AQP4-IGG阳性NMOSD的复发风险；并且B001较已获批同类药物具备更好的安全性，输液相关不良反应、感染相关不良反应、免疫球蛋白降低和血液学相关不良反应的发生率均更低。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0209","BK4134","BK0184","BK0020","BK0099","BK1197","601607","BK0097","BK0175","III","BK0012","BK0187","BK0196","BK0188","BK0028","BK0183","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638509247","title":"恒瑞III期临床试验成功，GLP-1百亿美元赛道再添玩家","url":"https://stock-news.laohu8.com/highlight/detail?id=2638509247","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638509247?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:14","pubTimestamp":1779876840,"startTime":"0","endTime":"0","summary":"5月27日，恒瑞医药与美国KaileraTherapeutics公司共同宣布：其口服小分子GLP-1受体激动剂HRS-7535在中国284名成人2型糖尿病受试者中开展的Ⅲ期临床试验OUTSTAND-1取得积极顶线结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605273751419649.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605273751419649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4134","BK4144","III","BK4590","GLP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638546521","title":"思路迪医药股份(01244)：恩维达®联合GEMOX一线治疗晚期胆道癌III期研究结果在2026年ASCO年会正式发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2638546521","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638546521?lang=zh_cn&edition=full","pubTime":"2026-05-27 08:20","pubTimestamp":1779841243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份 发布公告，本公司创新免疫新药恩维达的一项III期关键性临床研究成果，成功在2026年美国临床肿瘤学会年会上正式发布。晚期胆管癌预后差、临床治疗手段有限，未满足临床需求巨大，本次III期研究数据的公开，将进一步验证本品在肝胆肿瘤领域的临床价值，进一步拓展中国市场销售适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","01244","III","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637634193","title":"Inovio中国合作伙伴III期试验成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2637634193","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637634193?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:31","pubTimestamp":1779478260,"startTime":"0","endTime":"0","summary":"Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及大中华区净销售额的双位数分层特许权使用费。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhua5796224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334314","title":"阿斯利康将在ASCO 2026公布多项III期数据，涵盖肝癌、乳腺癌、膀胱癌及罕见病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334314","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334314?lang=zh_cn&edition=full","pubTime":"2026-05-22 23:33","pubTimestamp":1779463980,"startTime":"0","endTime":"0","summary":"阿斯利康于5月22日宣布，将在5月29日至6月2日举行的2026年美国临床肿瘤学会年会上，公布超过85篇摘要，涵盖10款已获批药物和13款潜在新药，其中包括25项口头报告。　　在肝癌方面，将公布EMERALD-3 III期试验结果。　　在膀胱癌方面，将公布POTOMAC III期试验的5年总生存期分析，该试验评估了Imfinzi联合卡介苗治疗高危非肌层浸润性膀胱癌的疗效。　　在罕见病方面，将展示anselamimab的III期临床项目数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyuwee5028220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1829250122.USD","LU2237443622.USD","LU0109394709.USD","BK4007","BK4568","LU2456880835.USD","LU2237443382.USD","AZN","BK4134","BK4588","IE00B3T34201.USD","LU2236285917.USD","LU2237443465.HKD","LU0058720904.USD","LU0889565916.HKD","LU2417539215.USD","LU0289739699.SGD","III","LU2462157665.USD","LU0320765992.SGD","LU2237443895.HKD","AZNH","LU2237443549.SGD","BK4585","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637362263","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超5% 恩沃利单抗新适应症III期临床完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637362263","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637362263?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:31","pubTimestamp":1779420681,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超4%，截至发稿，涨4.32%，报9.18港元，成交额811.35万港元。消息面上，5月22日，康宁杰瑞生物制药宣布，恩维达新辅助/辅助治疗可切除非小细胞肺癌的Ⅲ期临床研究，已完成全部患者入组。这一里程碑标志着恩维达在早期肺癌围手术期治疗领域取得重要进展，有望为肺癌患者带来更便捷、更安全的皮下免疫治疗新方案。目前恩维达还有多个临床研究在进行中，进一步拓展适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4134","BK4588","09966","III","BK1161","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334485","title":"安捷伦推出1290 Infinity III荧光检测器，实现UHPLC速度下的高信度痕量分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334485","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334485?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:07","pubTimestamp":1779372420,"startTime":"0","endTime":"0","summary":"安捷伦科技公司宣布推出Agilent 1290 Infinity III荧光检测器。这款新型检测器专为现代超高效液相色谱工作流程设计，将荧光检测技术带入UHPLC时代，为实验室提供痕量分析所需的更高置信度。传统荧光检测器并非为UHPLC方法的窄峰和快速分离而设计。1290 Infinity III FLD通过专为现代UHPLC优化的设计填补了这一空白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-21/doc-inhysnxc6275941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336990","title":"思路迪医药股份(01244)：恩维达®非小细胞肺癌新辅助╱辅助治疗III期临床研究提前完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336990","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637336990?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:43","pubTimestamp":1779367407,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份 发布公告，本公司与康宁杰瑞生物制药共同开发的恩维达用于可切除非小细胞肺癌患者新辅助╱辅助治疗的随机、对照、双盲、多中心III期临床研究已提前完成入组。本次III期临床研究由天津医科大学肿瘤医院王长利教授担任主要研究者，在全国约60家临床研究中心开展，计划入组约390例可切除III期非小细胞肺癌患者，实际入组人数符合研究方案要求，已提前完成入组工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","01244","BK1161","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636285087","title":"Bimzelx头对头III期研究告捷，斑块状银屑病关节炎指标显著优于Skyrizi","url":"https://stock-news.laohu8.com/highlight/detail?id=2636285087","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636285087?lang=zh_cn&edition=full","pubTime":"2026-05-19 23:01","pubTimestamp":1779202886,"startTime":"0","endTime":"0","summary":"　　比利时生物制药企业优时比公布了其IL-17A/IL-17F抑制剂Bimzelx的III期BE BOLD研究详细数据。结果显示，Bimzelx在治疗活动性银屑病关节炎患者的关键指标上，击败了艾伯维的重磅IL-23抑制剂Skyrizi。早在治疗第4周，Bimzelx组达到ACR50的患者比例便显著高于Skyrizi组。Bimzelx治疗组念珠菌感染的发生率较高，但均为轻中度，未导致停药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhymytc2158400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.1163},{"period":"3month","weight":-0.0624},{"period":"6month","weight":-0.1617},{"period":"1year","weight":-0.0363},{"period":"ytd","weight":-0.2197}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.030463},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.00444},{"month":5,"riseRate":0.368421,"avgChangeRate":-0.021525},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}